EGFR and breast cancer: In addition, the targeting of EDV was further achieved using bispecific antibodies, in which one arm recognizes the O-antigen component on the EDV surface LPS, and the other arm is a cell-surface receptor specific for the tumor cells to be targeted—for example, the human epidermal growth factor receptor 2 (HER2) or the epidermal growth factor receptor (EGFR) on ovarian and breast cancer cells, respectively (Figure 7B).